

## RESEARCH OPPORTUNITY

NAMI is committed to ensuring that the most effective treatments for mental illness are available to those who need them. Determining which treatments are most effective requires research. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and Chief Program Officer Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved by an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting clinical trial participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these trials.

If you have questions about research at NAMI, please visit [NAMI.org/research](https://www.nami.org/research) or email us at [research@nami.org](mailto:research@nami.org).

## WHAT IS THE STUDY?

This study is a clinical research trial for the investigational medication SEP-363856. The trial will determine if the medication is safe and effective for reducing symptoms of acute psychosis in adults with schizophrenia. Participants will be randomly assigned to receive one of the following: the investigational medication at 75mg daily, the investigational medication at 100mg daily, or a placebo, over the course of 6 weeks. Total participation time, including screening and follow-up, is about 9 weeks. Qualified participants may be compensated for their time and travel. The goal of this study is to increase treatment options available for people experiencing worsening psychotic symptoms of schizophrenia.

## WHO CAN PARTICIPATE?

Participants may be eligible for this study if they:

- Are aged 18 to 65 and meet criteria for schizophrenia
- Are experiencing worsening symptoms of psychosis
- Have not had more than 3 lifetime hospitalizations for acute psychosis/exacerbation of schizophrenia

Please note that these criteria are not complete. Certain additional factors may disqualify an individual from participation. For a full list of inclusion and exclusion criteria, please visit:

<https://www.clinicaltrials.gov/ct2/show/NCT04092686?term=SEP%3D363856&recrs=a&draw=2&rank=8>

## WHERE IS THE STUDY TAKING PLACE?

This study is taking place at a number of locations across the U.S. In your area, the study site is located in Gaithersburg, MD.

## HOW DO I LEARN MORE?

If you have questions or would like more information, please contact Dr. Acevedo Diaz Elia Enid at [e.acevedo@cenexel.com](mailto:e.acevedo@cenexel.com) or refer to the study website here:

<https://www.clinicaltrials.gov/ct2/show/NCT04092686?term=SEP%3D363856&recrs=a&draw=2&rank=8>